Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging.
Further, the company distributes recombinant human insulin APIs and porcine insulin API.
Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions.
The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | 0.96 Decreased by -16.52% | 1.00 Decreased by -4.00% |
| Aug 7, 24 | 0.94 Increased by +44.62% | 0.77 Increased by +22.08% |
| May 10, 24 | 1.04 Increased by +67.74% | 0.96 Increased by +8.33% |
| Feb 29, 24 | 0.88 Increased by +20.55% | 0.93 Decreased by -5.38% |
| Nov 8, 23 | 1.15 Increased by +202.63% | 0.69 Increased by +66.67% |
| Aug 8, 23 | 0.65 Increased by +66.67% | 0.56 Increased by +16.07% |
| May 9, 23 | 0.62 Increased by +31.91% | 0.48 Increased by +29.17% |
| Feb 28, 23 | 0.73 Increased by +73.81% | 0.41 Increased by +78.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 188.82 M Increased by +4.58% | 40.43 M Decreased by -17.86% | Increased by +21.41% Decreased by -21.46% |
| Jun 30, 24 | 182.39 M Increased by +25.17% | 37.95 M Increased by +45.26% | Increased by +20.81% Increased by +16.05% |
| Mar 31, 24 | 171.84 M Increased by +22.72% | 43.18 M Increased by +65.86% | Increased by +25.13% Increased by +35.15% |
| Dec 31, 23 | 178.10 M Increased by +31.91% | 36.17 M Increased by +6.65% | Increased by +20.31% Decreased by -19.15% |
| Sep 30, 23 | 180.56 M Increased by +50.30% | 49.22 M Increased by +210.08% | Increased by +27.26% Increased by +106.30% |
| Jun 30, 23 | 145.71 M Increased by +18.02% | 26.12 M Increased by +50.61% | Increased by +17.93% Increased by +27.61% |
| Mar 31, 23 | 140.02 M Increased by +16.33% | 26.03 M Increased by +7.34% | Increased by +18.59% Decreased by -7.73% |
| Dec 31, 22 | 135.02 M Increased by +11.69% | 33.91 M Increased by +71.62% | Increased by +25.12% Increased by +53.66% |